| Abstrakt: |
Dopamine D4receptor antagonists are being developed by several pharmaceutical companies as putative novel antipsychotics, possibly with low propensity to side‐effects. Two such compounds, L‐745,870 and U‐101958 have been recently introduced.The radioligand binding and functional activities of L‐745,870 and U‐101958 were investigated in human embryonic kidney (HEK)293 cells expressing the human recombinant dopamine D4.4receptor (HEK293/D4cells). [3H]‐spiperone binding experiments were performed and inhibition of forskolin‐stimulated cyclic AMP accumulation was used as the functional response.[3H]‐spiperone was found to label a homogeneous and saturable population of specific binding sites in HEK293/D4cell homogenates (Bmax505±90 fmol mg−1protein, pKD9.5±0.1, n=3). Inhibition of specific [3H]‐spiperone binding was observed with spiperone (pKi9.6±0.1, n=3), clozapine (pKi7.4±0.1, n=4), L‐745,870 (pKi8.5±0.1, n=3) and U‐101958 (pKi8.9±0.1, n=3). By contrast, raclopride was very weak (pKi<5, n=3).Dopamine inhibited forskolin‐stimulated cyclic AMP accumulation in HEK293/D4cells in a concentration‐dependent fashion (Emax71±2% inhibition of forskolin‐stimulated levels, pEC508.7±0.1, n=10). This effect was mimicked by the dopamine D2‐like receptor agonists, quinpirole and 7‐hydroxy‐2‐dipropylaminotetralin (7‐OH‐DPAT).L‐745,870 and U‐101958 also inhibited forskolin‐stimulated cyclic AMP accumulation in HEK293/D4cells in a concentration‐dependent way. L‐745,870 was less efficacious than dopamine (71% the efficacy of dopamine), whereas U‐101958 behaved as a full agonist compared to dopamine. Potencies (pEC50) values of L‐745,870 and U‐101958 were 9.0±0.2 (n=4) and 8.7±0.3 (n=3), consistent with pKivalues determined in radioligand binding studies.Dopamine, L‐745,870 and U‐101958 (up to 1 μM) were devoid of effect on forskolin‐stimulated cyclic AMP accumulation in control, non‐transfected HEK293 cells.The agonist effects of dopamine, L‐745,870 and U‐101958 in HEK293/D4cells could be antagonized by spiperone (pKB8.2–8.8) and clozapine (pKB7.1), but not by raclopride (pKB<5). None of these antagonists had any significant agonist activity at concentrations up to 10 μM.These results show that the putative dopamine D4receptor antagonists, L‐745,870 and U‐101958 are not devoid of intrinsic activity at human recombinant dopamine D4.4receptors. Therefore, they may not represent the most appropriate drugs for testing the benefit of D4receptor antagonism in schizophrenic patients, if agonism should translate in vivo. |
Plný text